发明申请
US20120165304A1 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
审中-公开
6,7,8,9-四氢-5H-1,4,7,10a-四氮杂 - 环庚烯并[f]茚衍生物，含有这些化合物的药物组合物，其用途和制备方法
![6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them](/docs/US/2012-06-28/US20120165304A1/abs.jpg.600x600.jpg)
- 专利标题： 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
- 专利标题（中）： 6,7,8,9-四氢-5H-1,4,7,10a-四氮杂 - 环庚烯并[f]茚衍生物，含有这些化合物的药物组合物，其用途和制备方法
-
申请号： US13130663申请日： 2009-11-26
-
公开(公告)号： US20120165304A1公开(公告)日： 2012-06-28
- 发明人: Stephan-Georg Mueller , Christopher John Brown , Alexander Heifetz , Bernd Nosse , Juergen Prestle , Natacha Prevost , Klaus Rudolf , Stefan Scheuerer , Marcus Schindler , Dirk Stenkamp , Leo Thomas , Heather Tye
- 申请人： Stephan-Georg Mueller , Christopher John Brown , Alexander Heifetz , Bernd Nosse , Juergen Prestle , Natacha Prevost , Klaus Rudolf , Stefan Scheuerer , Marcus Schindler , Dirk Stenkamp , Leo Thomas , Heather Tye
- 申请人地址： DE Ingelheim am Rhein
- 专利权人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 当前专利权人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 当前专利权人地址： DE Ingelheim am Rhein
- 优先权： EP08170154.2 20081127
- 国际申请： PCT/EP09/65883 WO 20091126
- 主分类号： A61K31/55
- IPC分类号： A61K31/55 ; C07D491/107 ; A61K31/551 ; A61P3/00 ; A61P25/00 ; C07D487/14 ; C07D495/04
![6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them](/abs-image/US/2012/06/28/US20120165304A1/abs.jpg.150x150.jpg)
摘要：
The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
信息查询
